Neurological Complications of Chemotherapy

  • Maria Diaz
  • David SchiffEmail author


As the outcomes for many cancers have improved, treatment-related toxicities and their impact on quality of life have become a more important part of oncologic care. Numerous chemotherapy regimens are associated with undesirable effects on the nervous system, often requiring modification of the treatment plan or even discontinuation of the offending drug. This chapter explores the neurotoxicities associated with certain chemotherapeutic agents, focusing on those that produce frequent or unique neurological complications; only cytotoxic treatments are reviewed, since targeted therapies and immunotherapies are discussed elsewhere. Drugs affecting predominantly the central nervous system are presented first, followed by the most common sources of chemotherapy-induced peripheral neuropathy. A description of the clinical characteristics and, when available, diagnostic and treatment strategies are included, to provide the reader with tools to recognize and manage these complications.


Neurotoxicity Chemotherapy Neuropathy Encephalopathy Brain Cancer 


  1. 1.
    Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol. 1986;22:815–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy. Anti-Cancer Drugs. 2004;15:347–50.PubMedCrossRefGoogle Scholar
  3. 3.
    David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005;28:277–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Tajino T, Kikuchi SI, Yamada H, Takeda A, Konno SI. Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. J Orthop Sci. 2010;15:104–11.PubMedCrossRefGoogle Scholar
  5. 5.
    Szabatura AH, Cirrone F, Harris C, McDonnell AM, Feng Y, Voit D, Neuberg D, Butrynski J, Fisher DC. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. J Oncol Pharm Pract. 2015;21:188–93.PubMedCrossRefGoogle Scholar
  6. 6.
    Sweiss KI, Beri R, Shord SS. Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature. Drug Saf. 2008;31:989–96.PubMedCrossRefGoogle Scholar
  7. 7.
    Nicolao P, Giometto B. Neurological toxicity of ifosfamide. Oncology. 2003;65(Suppl 2):11–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Taupin D, Racela R, Friedman D. Ifosfamide chemotherapy and nonconvulsive status epilepticus: case report and review of the literature. Clin EEG Neurosci. 2014;45:222–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Feyissa AM, Tummala S. Ifosfamide related encephalopathy: the need for a timely EEG evaluation. J Neurol Sci. 2014;336:109–12.PubMedCrossRefGoogle Scholar
  10. 10.
    Savica R, Rabinstein AA, Josephs KA. Ifosfamide associated myoclonus-encephalopathy syndrome. J Neurol. 2011;258:1729–31.PubMedCrossRefGoogle Scholar
  11. 11.
    Ames B, Lewis LD, Chaffee S, Kim J, Morse R. Ifosfamide-induced encephalopathy and movement disorder. Pediatr Blood Cancer. 2010;54:624–6.PubMedGoogle Scholar
  12. 12.
    Gonzalez-Angulo AM, Orzano JA, Davila E. Ifosfamide-induced encephalopathy. South Med J. 2002;95:1215–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Richards A, Marshall H, McQuary A. Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity. J Oncol Pharm Pract. 2011;17:372–80.PubMedCrossRefGoogle Scholar
  14. 14.
    McDonnell AM, Rybak I, Wadleigh M, Fisher DC. Suspected serotonin syndrome in a patient being treated with methylene blue for ifosfamide encephalopathy. J Oncol Pharm Pract. 2012;18:436–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Herzig RH, Hines JD, Herzig GP, Wolff SN, Cassileth PA, Lazarus HM, Adelstein DJ, Brown RA, Coccia PF, Strandjord S. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol. 1987;5:927–32.PubMedCrossRefGoogle Scholar
  16. 16.
    de la Sainz MCS, Jiménez Martín A, de Felipe Mimbrera A, Corral Corral Í. Cerebellar toxicity due to cytarabine: a series of 4 cases. Neurologia. 2016;31:491–2.CrossRefGoogle Scholar
  17. 17.
    Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol. 1997;15:833–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Honkaniemi J, Kähärä V, Dastidar P, et al. Reversible posterior leukoencephalopathy after combination chemotherapy. Neuroradiology. 2000;42:895–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Saito B, Nakamaki T, Nakashima H, Usui T, Hattori N, Kawakami K, Tomoyasu S. Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol. 2007;82:304–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Vaughn DJ, Jarvik JG, Hackney D, Peters S, Stadtmauer EA. High-dose cytarabine neurotoxicity: MR findings during the acute phase. AJNR Am J Neuroradiol. 1993;14:1014–6.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Hoffman DL, Howard JR, Sarma R, Riggs JE. Encephalopathy, myelopathy, optic neuropathy, and anosmia associated with intravenous cytosine arabinoside. Clin Neuropharmacol. 1993;16:258–62.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Chutorian AM, Bojko A, Heier L, Frucht S, Nygaard T, Edelberg D. Toxic pediatric parkinsonism: report of a child with metabolic studies and response to treatment. J Child Neurol. 2003;18:812–5.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Nevill TJ, Benstead TJ, McCormick CW, Hayne OA. Horner’s syndrome and demyelinating peripheral neuropathy caused by high-dose cytosine arabinoside. Am J Hematol. 1989;32:314–5.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Openshaw H, Slatkin NE, Stein AS, Hinton DR, Forman SJ. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer. 1996;78:1899–905.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Resar LMS, Phillips PC, Kastan MB, Leventhal BG, Bowman PW, Civin CI. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer. 1993;71:117–23.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Pound CM, Keene DL, Udjus K, Humphreys P, Johnston DL. Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2007;29:183–6.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Legrand F, Dorgeret S, Saizou C, Duval M, Vilmer E. Cerebellar herniation after intrathecal chemotherapy including cytosine arabinoside in a boy with T acute lymphoblastic leukemia. Leukemia. 2002;16:2454–5.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Jabbour E, O’Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;109:3214–8.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Gállego Pérez-Larraya J, Palma JA, Carmona-Iragui M, Fernández-Torrón R, Irimia P, Rodríguez-Otero P, Panizo C, Martínez-Vila E. Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma. J Neuro-Oncol. 2011;103:603–9.CrossRefGoogle Scholar
  30. 30.
    Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, Cantilena LR, Grem JL, Allegra CJ, Diasio RB, Chu E. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996;2:477–81.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Pirzada NA, Ali II, Dafer RM. Fluorouracil-induced neurotoxicity. Ann Pharmacother. 2000;34:35–8.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Suresh P, Kapoor R, Kapur BN. Irreversible cerebellar toxicity after infusional 5-fluorouracil therapy. Indian J Cancer. 2015;52:627–8.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Martinez-Lapiscina EH, Erro ME, Cabada T, Tuñón T. 5-fluorouracil induced hyperammonemic encephalophathy: etiopathologic correlation. Can J Neurol Sci. 2012;39:553–4.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Lucato LT, McKinney AM, Short J, Teksam M, Truwit CL. Reversible findings of restricted diffusion in 5-fluorouracil neurotoxicity. Australas Radiol. 2006;50:364–8.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Li J, Lee JJ, Chu E, Baehring JM. Reversible leukoencephalopathy with stroke-like presentation in a patient with 5-dihydropyrimidine dehydrogenase deficiency treated with continuous 5-fluorouracil infusion. Clin Colorectal Cancer. 2012;11:215–7.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Choi SM, Lee SH, Yang YS, Kim BC, Kim MK, Cho KH. 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci. 2001;16:328–34.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Videnovic A, Semenov I, Chua-Adajar R, et al. Capecitabine-induced multifocal leukoencephalopathy: a report of five cases. Neurology. 2005;65:1792–4; discussion 1685.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Beitinjaneh A, McKinney AM, Cao Q, Weisdorf DJ. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:300–8.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Lee MS, McKinney AM, Brace JR, Santacruz K. Clinical and imaging features of fludarabine neurotoxicity. J Neuroophthalmol. 2010;30:37–41.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Helton KJ, Patay Z, Triplett BM. Fludarabine-induced severe necrotizing leukoencephalopathy in pediatric hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48:729–31.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Saumoy M, Castells G, Escoda L, Marés R, Richart C, Ugarriza A. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma. 2002;43:433–6.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Vidarsson B, Mosher DF, Salamat MS, Isaksson HJ, Onundarson PT. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. Am J Hematol. 2002;70:51–4.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32:949–59.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Agarwal A, Vijay K, Thamburaj K, Ouyang T. Transient leukoencephalopathy after intrathecal methotrexate mimicking stroke. Emerg Radiol. 2011;18:345–7.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Inaba H, Khan RB, Laningham FH, Crews KR, Pui C-H, Daw NC. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol. 2008;19:178–84.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Patterson DM, Aries J, Hyare H, Holder D, Rees J, Lee SM. Nonconvulsive status epilepticus and leucoencephalopathy after high-dose methotrexate. J Clin Oncol. 2011;29:e459–61.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Oka M, Terae S, Kobayashi R, Sawamura Y, Kudoh K, Tha KK, Yoshida M, Kaneda M, Suzuki Y, Miyasaka K. MRI in methotrexate-related leukoencephalopathy: disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology. 2003;45:493–7.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology. 2004;62:548–55.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Lai R, Abrey LE, Rosenblum MK, DeAngelis LM. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology. 2004;62:451–6.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Cavaliere R, Schiff D. Neurologic toxicities of cancer therapies. Curr Neurol Neurosci Rep. 2006;6:218–26.PubMedCrossRefGoogle Scholar
  51. 51.
    Iuvone L, Mariotti P, Colosimo C, Guzzetta F, Ruggiero A, Riccardi R. Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia. Cancer. 2002;95:2562–70.PubMedCrossRefGoogle Scholar
  52. 52.
    Cachia D, Kamiya-Matsuoka C, Pinnix CC, Chi L, Kantarjian HM, Cortes JE, Daver N, Woodman K. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neuro-Oncol. 2015;122:391–8.CrossRefGoogle Scholar
  53. 53.
    Yi Y, Kang HJ, Shin HY, Kim K. Progressive myelopathy mimicking subacute combined degeneration after intrathecal chemotherapy. J Child Neurol. 2015;30:246–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Murata K, Maeba A, Yamanegi M, Nakanishi I, Ito H. Methotrexate myelopathy after intrathecal chemotherapy: a case report. J Med Case Rep. 2015;9:135.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Shintaku M, Toyooka N, Koyama T, Teraoka S, Tsudo M. Methotrexate myelopathy with extensive transverse necrosis: report of an autopsy case. Neuropathology. 2014;34:547–53.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Dicuonzo F, Salvati A, Palma M, Lefons V, Lasalandra G, De Leonardis F, Santoro N. Posterior reversible encephalopathy syndrome associated with methotrexate neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings. J Child Neurol. 2009;24:1013–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Antunes NL, Souweidane MM, Lis E, Rosenblum MK, Steinherz PG. Methotrexate leukoencephalopathy presenting as Klüver-Bucy syndrome and uncinate seizures. Pediatr Neurol. 2002;26:305–8.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G, Donati MB. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108:2216–22.PubMedCrossRefGoogle Scholar
  59. 59.
    Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, Deangelo DJ, Silverman LB. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152:452–9.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Kieslich M, Porto L, Lanfermann H, Jacobi G, Schwabe D, Böhles H. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2003;25:484–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Alsaid Y, Gulab S, Bayoumi M, Baeesa S. Cerebral sinus venous thrombosis due to asparaginase therapy. Case Rep Hematol. 2013;2013:841057.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Hourani R, Abboud M, Hourani M, Khalifeh H, Muwakkit S. L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children. Neuropediatrics. 2008;39:46–50.PubMedCrossRefGoogle Scholar
  63. 63.
    Frantzeskaki F, Rizos M, Papathanassiou M, Nikitas N, Lerikou M, Armaganidis A, Dimopoulos G. L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia. Am J Case Rep. 2013;14:311–4.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 1984;34:934–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rørth M, Krarup C. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain. 2007;130:1076–88.PubMedCrossRefGoogle Scholar
  66. 66.
    Oldenburg J, Kraggerud SM, Brydøy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med. 2007;5:70.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82:51–77.PubMedCrossRefGoogle Scholar
  68. 68.
    Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest. 1998;101:2842–50.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR, Tredici G. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer. 1992;69:203–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer. 1990;66:1117–23.PubMedCrossRefGoogle Scholar
  71. 71.
    Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2014:CD005228.Google Scholar
  72. 72.
    Paken J, Govender CD, Pillay M, Sewram V. Cisplatin-associated ototoxicity: a review for the health professional. J Toxicol. 2016;2016:1809394.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77:1355–62.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Berman IJ, Mann MP. Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer. 1980;45:764–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Cisplatin neurotoxicity. N Engl J Med. 1990;323:64–5.Google Scholar
  76. 76.
    Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, Yanagi T, Sobue G. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol. 1998;19:415–7.PubMedGoogle Scholar
  77. 77.
    Cerrud-Rodriguez RC, Quinteros MG, Azam M. Internal carotid artery occlusion and stroke as a complication of cisplatin-based chemotherapy for metastatic testicular germ cell tumour. BMJ Case Rep. 2017;2017:bcr-2017–220084.Google Scholar
  78. 78.
    Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119:438–44.PubMedCrossRefGoogle Scholar
  79. 79.
    Pachman DR, Qin R, Seisler DK, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance). J Clin Oncol. 2015;33:3416–22.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, Civitelli S, Tanzini G, Lorenzi M, Francini G. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol. 2008;61:105–11.PubMedCrossRefGoogle Scholar
  81. 81.
    Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006;27:992–1002.PubMedCrossRefGoogle Scholar
  82. 82.
    Heinzlef O, Lotz JP, Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry. 1998;64:667–9.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Vieillot S, Pouessel D, de Champfleur NM, Becht C, Culine S. Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol. 2007;18:608–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Fischer N, Stuermer J, Rodic B, Pless M. Carboplatin-induced bilateral papilledema: a case report. Case Rep Oncol. 2009;2:67–71.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013;37:231–9.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Velasco R, Bruna J. Taxane-induced peripheral neurotoxicity. Toxics. 2015;3:152–69.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM. Motor neuropathy due to docetaxel and paclitaxel. Neurology. 1996;47:115–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Reeves BN, Dakhil SR, Sloan JA, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012;118:5171–8.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Shin YS, Min KJ, Choi SY, Lee NW. Non-convulsive seizure related to Cremophor EL-free, polymeric micelle formulation of paclitaxel: a case report. Obstet Gynecol Sci. 2018;61:421–4.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Perry JR, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology. 1996;46:1596–9.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Fernandes R, Mazzarello S, Hutton B, Shorr R, Majeed H, Ibrahim MFK, Jacobs C, Ong M, Clemons M. Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer. 2016;24:3633–50.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    van den Bent MJ, Hilkens PHE, Sillevis Smitt PAE, van Raaij-van den Aarssen VJ, Bontenbal M, Verweij J. Lhermitte’s sign following chemotherapy with docetaxel. Neurology. 1998;50:563–4.PubMedCrossRefGoogle Scholar
  93. 93.
    Moloney TP, Xu W, Rallah-Baker K, Oliveira N, Woodward N, Farrah JJ. Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report. BMC Ophthalmol. 2014;14:18.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Vahdat LT, Thomas ES, Roché HH, et al. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer. 2012;20:2661–8.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Egerton N. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. Cancer Chemother Pharmacol. 2010;66:1005–12.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Vahdat LT, Garcia AA, Vogel C, Pellegrino C, Lindquist DL, Iannotti N, Gopalakrishna P, Sparano JA. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat. 2013;140:341–51.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Mora E, Smith EML, Donohoe C, Hertz DL. Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am J Cancer Res. 2016;6:2416–30.PubMedPubMedCentralGoogle Scholar
  98. 98.
    Verstappen CCP, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology. 2005;64:1076–7.PubMedCrossRefGoogle Scholar
  99. 99.
    Hancock BW, Naysmith A. Vincristine-induced autonomic neuropathy. Br Med J. 1975;3:207.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Trobaugh-Lotrario AD, Smith AA, Odom LF. Vincristine neurotoxicity in the presence of hereditary neuropathy. Med Pediatr Oncol. 2003;40:39–43.PubMedCrossRefGoogle Scholar
  101. 101.
    Moriyama B, Henning SA, Leung J, Falade-Nwulia O, Jarosinski P, Penzak SR, Walsh TJ. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses. 2012;55:290–7.PubMedCrossRefGoogle Scholar
  102. 102.
    Dixit G, Dhingra A, Kaushal D. Vincristine induced cranial neuropathy. J Assoc Physicians India. 2012;60:56–8.PubMedGoogle Scholar
  103. 103.
    Latiff ZA, Kamal NA, Jahendran J, Alias H, Goh BS, Syed Zakaria SZ, Jamal R. Vincristine-induced vocal cord palsy: case report and review of the literature. J Pediatr Hematol Oncol. 2010;32:407–10.PubMedCrossRefGoogle Scholar
  104. 104.
    Dhingra D, Sethi GR, Mantan M. Unilateral phrenic nerve palsy: a rare manifestation of vincristine neurotoxicity. Indian J Pediatr. 2014;81:957–8.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Adhikari S, Dongol RM, Hewett Y, Shah BK. Vincristine-induced blindness: a case report and review of literature. Anticancer Res. 2014;34:6731–3.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Escuro RS, Adelstein DJ, Carter SG. Syndrome of inappropriate secretion of antidiuretic hormone after infusional vincristine. Cleve Clin J Med. 1992;59:643–4.PubMedCrossRefGoogle Scholar
  107. 107.
    Ozyurek H, Oguz G, Ozen S, Akyuz C, Karli Oguz K, Anlar B, Aysun S. Reversible posterior leukoencephalopathy syndrome: report of three cases. J Child Neurol. 2005;20:990–3.PubMedCrossRefGoogle Scholar
  108. 108.
    Hennipman B, de Vries E, Bökkerink JPM, Ball LM, Veerman AJP. Intrathecal vincristine: 3 fatal cases and a review of the literature. J Pediatr Hematol Oncol. 2009;31:816–9.PubMedCrossRefGoogle Scholar
  109. 109.
    Pace A, Bove L, Nisticò C, Ranuzzi M, Innocenti P, Pietrangeli A, Terzoli E, Jandolo B. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry. 1996;61:409–11.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma. 2010;51:1178–87.PubMedCrossRefGoogle Scholar
  111. 111.
    Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144:895–903.PubMedCrossRefGoogle Scholar
  112. 112.
    Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116:4745–53.PubMedCrossRefGoogle Scholar
  113. 113.
    Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–40.PubMedCrossRefGoogle Scholar
  114. 114.
    Thawani SP, Tanji K, De Sousa EA, Weimer LH, Brannagan TH. Bortezomib-associated demyelinating neuropathy-clinical and pathologic features. J Clin Neuromuscul Dis. 2015;16:202–9.PubMedCrossRefGoogle Scholar
  115. 115.
    Oshikawa G, Kojima A, Doki N, Kobayashi T, Kakihana K, Tsuda H, Endo I, Kamata N, Ohashi K, Sakamaki H. Bortezomib-induced posterior reversible encephalopathy syndrome in a patient with newly diagnosed multiple myeloma. Intern Med. 2013;52:111–4.PubMedCrossRefGoogle Scholar
  116. 116.
    Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98:1753–61.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621–34.PubMedCrossRefGoogle Scholar
  118. 118.
    Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology. 2007;69:573–81.PubMedCrossRefGoogle Scholar
  119. 119.
    Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, Schmidt-Wolf I, Gorschlüter M. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2006;132:584–93.PubMedCrossRefGoogle Scholar
  120. 120.
    Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009;27:1788–93.PubMedCrossRefGoogle Scholar
  121. 121.
    Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23:2147–52.PubMedCrossRefGoogle Scholar
  122. 122.
    Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–66.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of NeurologyMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.University of Virginia Neuro-Oncology CenterCharlottesvilleUSA

Personalised recommendations